Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07576959 Vonoprazan Fumarate Helicobacter pylori infection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07576959 clinical trial report covering Vonoprazan Fumarate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07575009 Penicillin G Sodium Infectious Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07575009 clinical trial report covering Penicillin G Sodium, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Daratumumab Biologics Sequence Review Report 2026: CD38 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Daratumumab, an antibody targeting CD38.
Latest Hotspot
8 min read
NCT07575399 Maridebart Cafraglutide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07575399 clinical trial report covering Maridebart Cafraglutide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07576660 Dexamethasone Sodium Phosphate Respiratory Distress Syndrome, Acute Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07576660 clinical trial report covering Dexamethasone Sodium Phosphate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Motavizumab Biologics Sequence Review Report 2026: RSV F protein Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Motavizumab, an antibody targeting RSV F protein.
Latest Hotspot
8 min read
NCT07575672 Finerenone Heart failure with normal ejection fraction Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07575672 clinical trial report covering Finerenone, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07576764 Melatonin Sleep Initiation and Maintenance Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
NCT07576764 clinical trial report covering Melatonin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
6 min read
Ublituximab Biologics Sequence Review Report 2026: CD20 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ublituximab, an antibody targeting CD20.
6 min read
Ocrelizumab Biologics Sequence Review Report 2026: CD20 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ocrelizumab, an antibody targeting CD20.
6 min read
Ofatumumab Biologics Sequence Review Report 2026: CD20 Similarity and Patent-Risk Signals
22 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ofatumumab, an antibody targeting CD20.
Latest Hotspot
8 min read
CTR20261743 Isosulfan Blue Chylous Ascites Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
22 July 2026
CTR20261743 clinical trial report covering Isosulfan Blue, Phase 3, endpoints, sponsor, geography, readout timing and development white space.